Yuvezzi for Presbyopia Now Available in US

Why It Matters

By delivering a prescription‑strength, once‑daily drop, Yuvezzi could shift presbyopia management away from glasses and invasive procedures, opening a new revenue stream in a multi‑billion‑dollar market.

Key Takeaways

• First FDA‑approved dual‑ingredient presbyopia eye drop.
• Provides up to 10‑hour near vision after 30 minutes.
• Available via Tenpoint’s e‑pharmacy PHILRx and retail stores.
• Daily single drop simplifies reading‑glasses alternatives.
• Sample program launched for optometrists nationwide.

Pulse Analysis

Presbyopia affects roughly 1.8 billion adults worldwide, and in the United States alone more than 100 million people struggle with near‑vision loss as they age. Historically, the condition has been managed with reading glasses, multifocal lenses, or invasive procedures such as conductive keratoplasty and lens‑replacement surgery. While these options restore near focus, they carry cost, convenience, or safety trade‑offs that leave a sizable segment of consumers seeking non‑surgical alternatives. In this context, the FDA’s clearance of an eye‑drop therapy marks a pivotal shift, introducing a pharmacologic route that could redefine standard care for age‑related vision decline.

Yuvezzi combines 2.75 % carbachol with 0.1 % brimonidine tartrate, a dual‑action formula that simultaneously induces miosis and relaxes the ciliary muscle. Carbachol stimulates the iris sphincter, shrinking the pupil to increase depth of focus, while brimonidine blocks the dilator muscle, prolonging the constriction and reducing accommodative lag. Clinical data show a single drop produces measurable pupil constriction within 30 minutes that persists for up to ten hours, effectively covering a typical workday without repeat dosing. The product’s distribution through Tenpoint’s PHILRx e‑pharmacy and conventional retail chains streamlines access, positioning it as a convenient over‑the‑counter‑style prescription for optometrists and ophthalmologists.

From a commercial perspective, Tenpoint Therapeutics stands to capture a sizable share of the $5 billion U.S. presbyopia market, especially as insurers begin to reimburse prescription eye drops for age‑related vision loss. Early adoption by eye‑care professionals will be driven by the company’s sample‑distribution program and educational outreach, which aim to embed Yuvezzi into routine refraction exams. Competitors may respond with alternative pharmacologic candidates, but Yuvezzi’s dual‑ingredient approach and FDA clearance give it a first‑mover advantage. If real‑world adherence mirrors trial results, the therapy could generate recurring revenue streams while reducing reliance on glasses and surgical interventions, reshaping the economics of vision correction.